Table 1 Patient characteristics

From: A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD)

Patient Age Cytogenetics Pre-therapy MRD (%) # Prior therapy courses Post- therapy MRD (%) Clof/Cy/Etop dosing (mg/m2) Graft source Time to HCT (days) Grade 3/4 toxicities a Disease status
1 14 years del 6 0.18 3 NED 30/340/100 UCB 43 None Alive
2 23 months t(4;11q23), MLL-R 0.06 3 NED 1/10/3.3b UCB 88c None Alive
3 17 years i(7), gain 17p 3.00 3 NED 30/300/100 MSD, PBSC 69 F/N, transient RI, tenosynovitis Alive
4 5 years t(11q23;19), MLL-R 1.40 3 NED 30/300/100 MUD, BM 41 None Relapsed/Alive
5 7 years -X, t(7;11q23) 0.28 2 0.02 30/300/100 UCB 53 Mandibular osteomyelitis TRM
6 18 years IKAROS del loss of CDKN2A 0.93 3 NED 30/340/100 DUCB 64 Sinusitis, rash (cheeks) TRM
7 11 years t(9;22) Ph+ 0.14 2 0.07 20/340/100 UCB 53 None Relapsed/Died
8 20 years 47, XY (+21) 0.11 2 NED 30/300/100 MUD 201d Zoster Alive
  1. Abbreviations: DUCB=double umbilical cord blood; F/N=fever and neutropenia; MSD=matched sibling donor; MUD=matched unrelated donor; NED=no evidence of disease; RI=renal insufficiency; TRM=transplant-related mortality; UCB=umbilical cord blood.
  2. aCommon terminology criteria for adverse events version 4.0.
  3. bDosing was in mg/kg.
  4. cThis patient received a second course of bridging therapy while MRD negative as they awaited donor collection for HCT.
  5. This patient received ALL maintenance type therapy after bridging treatment and MRD negative secondary to developing zoster and unable to go directly to HCT.